Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Sleep Study
NCT03968744Phase 4Terminated
- Start
- Feb 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of safinamide in Parkinson's disease (PD). Primary endpoint: Overall Sleep Quality at 12 weeks. Started Feb 2019; status: terminated.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03968744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968744.